194 related articles for article (PubMed ID: 22615544)
21. Neglected tropical diseases: becoming less neglected.
The Lancet
Lancet; 2014 Apr; 383(9925):1269. PubMed ID: 24725560
[No Abstract] [Full Text] [Related]
22. [Research & development and distribution of medicines for eliminating tropical diseases: Introduction of our activities as an example of the approach by pharmaceutical industries].
Asada M
Nihon Yakurigaku Zasshi; 2017; 149(5):225-230. PubMed ID: 28484105
[No Abstract] [Full Text] [Related]
23. The German government's global health strategy--a strategy also to support research and development for neglected diseases?
Fehr A; Razum O
Glob Health Action; 2014; 7():24565. PubMed ID: 25079287
[TBL] [Abstract][Full Text] [Related]
24. Tropical disease: A neglected cause.
Laursen L
Nature; 2016 May; 533(7602):S68-9. PubMed ID: 27167396
[No Abstract] [Full Text] [Related]
25. Drug discovery in the clouds.
McCarthy A
Chem Biol; 2012 Jan; 19(1):1-2. PubMed ID: 22284348
[No Abstract] [Full Text] [Related]
26. WHO's role in the global health system: what can be learned from global R&D debates?
Moon S
Public Health; 2014 Feb; 128(2):167-72. PubMed ID: 24393496
[TBL] [Abstract][Full Text] [Related]
27. Introduction: pharmaceutical innovation: law & the public's health.
Outterson K
J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
[No Abstract] [Full Text] [Related]
28. Policy coherence for improved medical innovation and access.
Mirza Z; Krattiger A; Taubman A; Bartels HG; Beyer P; Kampf R; Watal J
Bull World Health Organ; 2013 May; 91(5):315-315A. PubMed ID: 23678191
[No Abstract] [Full Text] [Related]
29. [Bringing Japan's R&D innovation and leadership to combat neglected diseases].
Katsuno K
Nihon Yakurigaku Zasshi; 2017; 149(5):231-234. PubMed ID: 28484106
[No Abstract] [Full Text] [Related]
30. Investment in drugs for neglected diseases: a portrait of the last five years.
Brito MA
Rev Soc Bras Med Trop; 2013; 46(1):1-2. PubMed ID: 23563816
[No Abstract] [Full Text] [Related]
31. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
Grover A; Citro B; Mankad M; Lander F
J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
[TBL] [Abstract][Full Text] [Related]
32. Can India lead the way in neglected diseases innovation?
Thomas Z; Saha GK; Gopakumar KM; Ganguly NK
BMJ; 2019 Jan; 364():k5396. PubMed ID: 30670384
[No Abstract] [Full Text] [Related]
33. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.
Robertson AS
Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641
[TBL] [Abstract][Full Text] [Related]
34. [Development and Distribution of Drugs for NTDs: Efforts of One Pharmaceutical Company].
Asada M
Yakugaku Zasshi; 2016; 136(2):223-30. PubMed ID: 26831797
[TBL] [Abstract][Full Text] [Related]
35. Contemporary challenges on access to medicines: beyond the UNSG High-Level Panel.
Bermudez J
Cien Saude Colet; 2017 Aug; 22(8):2435-2439. PubMed ID: 28793061
[TBL] [Abstract][Full Text] [Related]
36. Report calls for US funding to speed global health research and innovation.
Mitka M
JAMA; 2011 Jun; 305(23):2399, 2401. PubMed ID: 21673287
[No Abstract] [Full Text] [Related]
37. Pharma backs latest attempt at a global health R&D treaty.
Hersher R
Nat Med; 2012 Jun; 18(6):838. PubMed ID: 22673977
[No Abstract] [Full Text] [Related]
38. MeTA: a welcome force for access to medicines.
Lancet; 2008 May; 371(9626):1724. PubMed ID: 18502276
[No Abstract] [Full Text] [Related]
39. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
Ioset JR; Chang S
Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842
[TBL] [Abstract][Full Text] [Related]
40. [Activity of NTDs Drug-discovery Research Consortium].
Namatame I
Yakugaku Zasshi; 2016; 136(2):231-6. PubMed ID: 26831798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
